News | October 07, 2023
Amgen completes acquisition of Horizon Therapeutics
Advances Amgen's mission to serve patients with rare disease medicines
Advances Amgen's mission to serve patients with rare disease medicines
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Franson will help biopharma clients design a phased approach to inform and execute clinical development plans
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)